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Abstract Women of childbearing age experience an in-
creased breast cancer risk associated with a completed
pregnancy. For younger women, this increase in breast
cancer risk is transient and within a decade after parturition
a cross over effect results in an ultimate protective benefit.
The post-partum peak of increased risk is greater in women
with advanced maternal age. Further, their lifetime risk for
developing breast cancer remains elevated for many years,
with the cross over to protection occurring decades later or
not at all. Breast cancers diagnosed during pregnancy and
within a number of years post-partum are termed
pregnancy-associated or PABC. Contrary to popular belief,
PABC is not a rare disease and could affect up to 40,000
women in 2009. The collision between pregnancy and
breast cancer puts women in a fear-invoking paradox of
their own health, their pregnancy, and the outcomes for
both. We propose two distinct subtypes of PABC: breast
cancer diagnosed during pregnancy and breast cancer
diagnosed post-partum. This distinction is important be-
cause emerging epidemiologic data highlights worsened
outcomes specific to post-partum cases. We reported that
post-partum breast involution may be responsible for the
increased metastatic potential of post-partum PABC. In-
creased awareness and detection, rationally aggressive
treatment, and enhanced understanding of the mechanisms
are imperative steps toward improving the prognosis for
PABC. If we determine the mechanisms by which involu-
tion promotes metastasis of PABC, the post-partum period




PABC Pregnancy associated breast cancer
BRCA1 Breast cancer type 1 susceptibility protein
BRCA2 Breast cancer type 2 susceptibility protein
IGF-1 Insulin like growth factor 1
ECM Extracellular matrix
BMI Body mass index
MMP Matrix metalloproteinase
The interactions between pregnancy and breast cancer are
complex and variable. More often than is frequently
realized, these interactions are negative with regard to the
resultant outcomes. The influence of pregnancy on the risk
of developing breast cancer is dependent on maternal
features, including age, family history, lactation post-
partum, and overall parity. The risk for future breast cancer
after a pregnancy follows a pattern curve of increased then
decreased risk over time, with the zenith and subsequent
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Even more complex, perhaps, is the interaction of breast
cancer cases with concomitant pregnancy or cases diag-
nosed closely thereafter. The increased incidence and
metastatic potential from these tumors has been well
outlined in epidemiologic research with the search for
mechanisms ongoing. We will review the known interac-
tions of pregnancy and breast cancer for both the effect of
pregnancy on incidence and prognosis of the disease.
Epidemiologic evidence, data on identified and potential
mechanisms underpinning these events, and our hypotheses
as to the role of involution in these events will be discussed.
Epidemiology of Pregnancy and Breast Cancer
Incidence: the Dual and Cross-over Effects
Completion of a pregnancy invokes two potentially opposing
effects onthe mother’s subsequentriskofbreastcancer, hence
t h ed u a le f f e c to fp r e g n a n c y .M o s tf a m i l i a ri nb r e a s tc a n c e r
risk tables is the association of parity with a lifetime reduction
in breast cancer risk. However, studies of breast cancer
incidence in young women demonstrate a clinically under-
recognized transient increase in breast cancer risk in the years
immediately following pregnancy where all parous women,
regardless of age, have higher incidence of breast cancer
compared with nulliparous women [1–4]. This increase in
risk has been shown to persist for at least ten [2, 3] and up to
15 years after birth in women under age 25 at delivery [1].
Unfortunately, delayed childbearing further increases this
transient risk for subsequent breast cancer, with maternal age
greater than 30 at first birth resulting in both an elevation of
the peak incidence in the initial years post-partum and a
longer tail effect of increased risk persisting for 30–50 years
post-partum [1–5].
Evolving epidemiologic research demonstrates differ-
ences in incidence risk during this post-partum transient
peak, dependent upon which additional variables are
analyzed. In addition to maternal age, total number of
pregnancies and family history are important contributors to
the risk effect of pregnancy on breast cancer incidence. In
one study of uni-parous women, the transient increase in
risk peaked at 5 years after first delivery and leveled off
15 years after delivery [4]. Women who were bi-parous,
regardless of age at second birth, had a lower magnitude of
transient increase in risk [1] that also peaked earlier, at
3 years post-partum [4]. This alteration in risk profile is
possibly due to an overlap, or stacking, of effects conferred
by their first pregnancy. The transient increase in breast
cancer incidence following childbirth is worsened by a
concomitant family history of breast cancer [6]. Moreover,
advanced maternal age and family history act synergisti-
cally to increase risk. Women 30 years of age or older at
first birth with a family history have a three-fold increased
risk over those with no family history, and this risk persists
longer, for 20–30 years post-partum [5, 6]. Furthermore,
women with germline mutations in the breast cancer
susceptibility genes BRCA1 or BRCA2 experience a
similar transient increase in breast cancer incidence com-
pared to their high risk, nulliparous controls [7, 8].
Though the initial effect of any completed pregnancy on
breast cancer incidence is an increased risk, a cross-over to
a long-term protection occurs for women of younger
maternal age at first birth, which has been referred to as
the cross-over effect. Uni-parous women who complete
their first pregnancy before age 25 still experience a
transient increase in risk, however they are subsequently
rewarded with a lifetime risk reduction of 36% for
developing breast cancer [9]. Likewise, increasing parity
also confers long term risk reduction, decreasing a women’s
lifetime risk of developing breast cancer by 7.0% for each
additional birth [10]. Age and parity appear to act
synergistically with high parity [≥5] and young age [≤20]
at first birth associated with the greatest ultimate reduction
in lifetime breast cancer risk. This protective effect is
weakened among multiparous women if their age at first
birth is greater than 30 [11]. A family history of breast
cancer lowers but does not negate the overall lifetime
protective effect with increasing parity [6]. Reduction in
lifetime risk for breast cancer with any degree of parity has
been variably reported for BRCA1 and BRCA2 mutation
carriers [12–14]. (Table 1)
Conversely, advanced maternal age at first birth nearly
abrogates the lifetime breast cancer protection as first
pregnancy above age 35 results in loss or significant delay
in the cross over effect [15, 16]. These studies note a tail
effect of increased risk for up to 50 years post-partum [4,
17], well into the decades of life when breast cancer is
Table 1 Lifetime breast cancer risk associated with age at first
pregnancy.
Risk separated by age (median)
Age General
population












a 2.7 1.96 2.85
<20 1.06 0.53 1
a 1
a
20–24 1 2.1 1.08 1.74
25–30 1.11 2.1 1.08 1.48
>30 1.19–2.19
c 4 0.83 4.77
aRisk was set to 1 as reference and varies between studies,
bFamily
member diagnosed before age 50,
cRepresented as a range since some
studies reported >30 and others >35.
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protective effect of pregnancy against breast cancer will not
occur in an average lifetime. Research such as the Shanghai
Breast Cancer Study demonstrates how cultural shifts in
countries with low incidence of breast cancer and histori-
cally young onset of childbearing to more advanced
maternal age are also noting an increase in breast cancer
incidence [18]. Overall each year of increased maternal age
at first birth results in an estimated 3.5%–5.3% increase in
lifetime relative risk for breast cancer [19, 20]. In terms of
lifetime breast cancer risk, the age of 35 years acts as a
critical point; prior to this age full-term pregnancy offers
women some degree of protection, but after this age full-
term pregnancy is associated with a permanent increase in
breast cancer risk [19].
At present, several conclusions can be drawn from the
available epidemiologic data on the impact of pregnancy
with breast cancer incidence. All women who complete a
pregnancy are in a transient period of moderate increased
breast cancer risk compared to their nulliparous peers. The
degree of increased risk is akin to other routine breast
cancer risk factors, such as early menarche and number of
first degree relatives affected before age 50. However, the
risks related to pregnancy history are not currently
incorporated into clinical tools for assessing a woman’s
risk for the development of breast cancer. Greater under-
standing of this transient increase is needed for subsequent
adaptation into clinical breast cancer risk assessment.
Moreover, attention to this breast cancer risk factor is
warranted in the assessment of young women presenting
with breast complaints in the post-partum years and
consideration of such risk along with the clinical guidelines
for evaluation of such complaints is required to avoid false
reassurance or delayed diagnosis.
What Underlies the Epidemiologic Data?
There are several possible and likely intertwined hypothe-
ses as to underlying mechanisms driving the dual effect.
The transient increase in breast cancer risk experienced by
all parous women appears to be due to an event or events
associated with pregnancy. Candidate contributors to the
increased incidence include: pregnancy-related hormones
such as estrogen, progesterone, and growth hormone that
promote previously initiated cells, immune suppressive
effects of pregnancy, and the post-partum involution
process [17, 21, 22]. Research on the role of pregnancy
related hormones has shown that increased exposure to
estrogen, progesterone, and insulin like growth factor 1
(IGF-1), that is increased in pregnancy in response to
growth hormone, are associated with promotion of breast
cancer cell proliferation [17]. Therefore, it is possible that
the transient increased risk for breast cancer observed with
a recent pregnancy is due to the significant increase in
concentrations of these hormones during pregnancy, result-
ing in high-level exposures and subsequent tumor initiation
and/or promotion. Alternatively, we and others have
reported on an event inherently related to pregnancy that
may contribute to growth and development of breast cancer
cells. This event is post-partum/post-lactational involution.
Involution mimics aspects of wound healing and immuno-
suppression, which are both known to be pro-tumorigenic.
We hypothesize that the tissue microenvironment of
involution, with its associated immune cell influx, activated
fibroblasts, extracellular matrix (ECM) deposition, elevated
matrix metalloproteinase levels and bioactive matrix frag-
ments resembles a pro-tumorigenic wounding environment,
and may be responsible for the increased incidence and/or
poor prognosis of breast cancer with recent pregnancy [17,
23]. This Involution Hypothesis is discussed further below.
There are several hypotheses put forth to explain the
biological processes responsible for why young women
experience the benefit of the cross-over effect significantly
more than older first time mothers. First, full term
pregnancy induces terminal differentiation of the mammary
gland, which is thought to render the gland less susceptible
to tumorigenesis [24–26]. Young mothers receive benefit
due to the shorter exposure time between puberty and full
term pregnancy, the window of peak susceptibility [26, 27].
Conversely, the persistent risk for advanced maternal age is
believed to be due to increased exposure time of breast
tissue to potential mutagens before the terminal differenti-
ation of the gland by pregnancy. This belief is backed up by
evidence that any interval of >16 years between menarche
and first birth, regardless of the specific ages when those
events occurred, results in an increased risk for breast
cancer [27]. Thus, in older first time mothers, there is
theoretically a greater chance for pre-malignant breast
lesions to develop before a completed pregnancy occurs,
which would be subsequently promoted either by the
pregnancy or an event associated with that pregnancy, such
as post-partum gland involution. Second, increasing parity
overall reduces lifetime menstrual cycling which may
impact lifelong breast cancer risk via reducing exposure to
the cycling of hormones associated with both the luteal
(progesterone and to a lesser extent estrogen) and follicular/
ovulatory (estradiol) phases of menstruation [21, 22].
Finally, there is recent evidence in rodents suggesting that
a decrease in mammary stem cells occurs with early parity
[28]. If one accepts the mammary tumor stem cell
hypothesis, which proposes that stem cells in the mammary
gland are the targets for transformation [29–33], then a
global reduction in the number of mammary gland stem
cells would be anticipated to reduce a woman’s lifetime
risk.
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underpinning the dual effect and cross over effect of
pregnancy on breast cancer. Objectives would be to define
chemotherapeutics aimed at abrogation of the transient risk
and enhancement of the protective effects of pregnancy.
Hopeful results of this research would result in a reduction in
diagnosis of PABC and young women’sb r e a s tc a n c e ro v e r a l l .
Lactation and Breast Cancer Risk: a Prevention
Strategy?
In contrast to the relatively robust body of data outlining
the effects of pregnancy on breast cancer incidence, the
distinct role that lactation contributes has been harder to
isolate. Overall, lactation is attributed with a wide range of
relative risk reductions, ranging from 4.3–64% in 89
reported studies to date [10, 34, 35]. Meta-analyses on
these studies revealed multiple benefits, including that a
protective effect was conferred by lactation with reductions
in relative risk for pre-menopausal breast cancer as high as
64% [34]. These studies demonstrate that a woman’s
relative risk can be decreased by 4.3% for every 12 months
of lactation [10], and that any degree of lactation but
particularly extended lactation can be protective [35].
However, some of the studies examined in these meta-
analyses revealed no correlation between lactation and
reduction of a woman’s risk for breast cancer [34, 35].
These epidemiologic studies on lactation are complicated,
and potentially inconclusive, when viewed en masse due to
issues that include inherently varying definitions of lacta-
tion, inability to control for potentially important cofound-
ers such as body mass index (BMI), exclusivity of lactation,
lifetime level versus per pregnancy exposure, and concom-
itant medications or medical conditions, to name a few.
In addressing the overlapping epidemiologic effects of
pregnancy and lactation, it can be postulated that for
women at increased risk for breast cancer due to recent
childbirth, post-partum lactation would mitigate this in-
crease. One study of the effect of lactation on the transient
increased risk of breast cancer in the 5 year interval from
most recent child-birth showed that any duration of
lactation conferred reduction against the peak increase in
PABC risk [3]. Specifically, within 5 years of parturition,
absence of lactation conferred an overall risk of 1.64, while
presence of lactation reduced this risk to 1.24. The trend
continued but the effect was reduced by 5–10 years post-
partum. After 10 years post-partum the effect was lost,
indicating that the protective effect of lactation is most
noted on the transient post-partum period of increased risk
for developing breast cancer and limited to nil on lifetime
risk of breast cancer [36]. Women with germline mutations
in BRCA1 and BRCA2 do not as clearly benefit from
lactation [12, 37]. One potential confounder of this data is
the grouping of BRCA1 and BRCA2 mutation carriers as
one, given that independent assessment of BRCA1 muta-
tion carriers demonstrated a 44–50% reduction in risk for
breast cancer observed with lactation duration > 1 year, a
greater risk reduction than observed in some studies of the
general population [38, 39].
Several hypotheses could explain the protective effect of
lactation on transient and overall breast cancer risk. First,
similar to pregnancy, lactation promotes terminal differen-
tiation of mammary epithelial cells, potentially rendering
them less susceptible to carcinogenic stimuli [40]. This
hypothesis is supported by data indicating that very early
age at first breastfeeding, <20 years is protective beyond
that afforded by maternal age at first pregnancy alone [40–
42]. Second, length of lactation further decreases a
woman’s lifetime exposure to cycling hormones over
pregnancy alone by further suppression of ovulation. An
intriguing aspect to this hypothesis comes from the data on
women with BRCA1 mutations, where lengthy lactation
conferred large benefit [38]. Given the overwhelming
propensity for BRCA1 carriers to have hormone receptor
negative tumors, the data suggests that another ovarian
axis-driven mechanism besides stimulation of tumor cells
accounts for the protection afforded by lactation. The
known protection from breast cancer observed in BRCA1
carriers through prophylactic oophorectomy, which results
in a 56–60% decrease for development of breast cancer,
supports this possibility [39, 43, 44]. Third, in a recently
developed mouse model with a precocious lactogenic
phenotype, knock-out of Caveolin 3 renders the mice
resistant to mammary tumor formation induced by ortho-
topic tumor cell implantation into the mammary gland [45,
46]. This study indicates that the lactation environment is
tumor protective in rodents. One may also postulate that the
prolongation of time between two tumor promoting events,
pregnancy and involution, by increased length of lactation
lessens the chances of these two events acting synergisti-
cally to promote progression of previously initiated cells.
Lastly, in the case of longer lactation that may naturally
dwindle with maturity of the child, could a gradual decrease
in lactational pull invoke a less robust involution program
than that induced with abrupt cessation?
In summary, lactation may provide a reduction in a
woman’s transient risk and lifetime chance for developing
pre-menopausal breast cancer, with varying degrees of
evidence currently available. Interestingly, it has been
reported that the United States has a low proportion, only
50%, of parous women who have ever breast fed [10].
From these data, it is possible to hypothesize that any
measure instituted to promote breastfeeding practices could
also be considered a potential breast cancer prevention
strategy.
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and Pregnancy-Associated Breast Cancer: Two Bad
Things that Go Together
Breast cancer is the leading cause of cancer death in US
women age 15–29. In 2005, the US alone was estimated to
have 11,110 breast cancer cases identified in women under
40 with a concomitant 1,110 deaths. Statistics from similar
countries world-wide show near identical rates of incidence
and death in young women due to breast cancer [47]
Moreover, despite the recent reduction in total incidence of
breast cancer, mostly attributable to women over age 50
[48], the annual incidence in the under 40 age range is not
decreasing and the absolute number of affected women
herein is increasing [49, 50].
Regardless of how one chooses to draw the upper limit
of age for young women’s breast cancer, this population
reflects the dominant child-bearing portion of humanity. In
2005, the US reported nearly 5,000 cases of breast cancer
diagnosed during pregnancy, making it the second most
common co-diagnosed cancer [51]. However, pregnancy-
associated breast cancer is more than cases diagnosed
during pregnancy. Emerging epidemiologic and prospective
research is providing enhanced insight into this subset of
young women’s breast cancer, allowing it to progress as an
important focus for goals of prevention, therapeutics, and
survivorship interventions in the future.
PABC Subset #1: Outcomes when Breast Cancer
is Diagnosed During Pregnancy
When breast cancer is diagnosed concomitantly with
pregnancy and is treated with definitive intent to both
satisfactorily offer disease control and maintain the preg-
nancy, long terms outcomes appear equivalent based on
age-matched, stage-matched non-pregnant controls [52,
53]. Guidelines on the acceptable management of breast
cancer during pregnancy have been published and long-
term outcomes in both the treated mothers and their co-
treated offspring are favorable [54]. These observations
support the ongoing effort to offer pregnancy preservation
in the setting of breast cancer therapy when stage of disease
at presentation and desires of the patient and involved
parties for the child are compatible.
Identified issues that complicate breast cancer diagnosis
during pregnancy include delay in diagnosis and subse-
quent trend toward later stage, including higher incidence
of nodal involvement [55, 56]. Differences as high as an
average delay of 5–7 months and 2.5 fold risk of advanced
disease have been reported [55–58]. Likewise, enrichment
for negative biologic features that worsen prognosis,
including higher grade, lower percentage of hormone-
receptor positivity, increased Her 2 neu over-expression,
and higher Ki-67 nuclear antigen indices are present [59–
61]. However, if pregnancy alone is an isolated variable
with cases matched by stage, age, and year of diagnosis
then the diagnosis of breast cancer during pregnancy is not
associated with poorer maternal outcome than non-PABC
cases [17, 55, 56, 58, 62–65].
Importantly, while some published studies that included
women diagnosed during pregnancy have indicated worse
maternal outcomes for PABC, these studies either did not
match specifically on the known biologic drivers of
metastasis and/or included women who were post-partum
but lactating or within 1 year of parturition as cases in the
same group as women diagnosed when pregnant [66–68].
A recent prospective French study of 40 PABC cases,
where PABC was defined as breast cancer occurring during
pregnancy or 1 year after delivery, noted overall survival
rates of 72% for PABC versus 97% for age-matched
controls (Table 2)[ 68]. This study provides an excellent
detailed review of PABC cases, both those diagnosed
during pregnancy versus post-partum compared with age
matched controls. Overall, the difference in outcomes
between groups (combined as both during pregnancy and
post-partum) could be correlated with the pregnant PABC
cases being enriched for high grade tumors and both PABC
subsets enriched for hormone-receptor poor tumors. Like-
wise, though the mean gestation age at diagnosis was
22 weeks, only three cases received chemotherapy during
pregnancy versus 31 post-partum cases, suggesting that a
delay of chemotherapy initiation due to pregnancy may be
present, and may confound interpretations. The authors also
acknowledge that differences in anti-endocrine therapy
were present, and both issues may occlude disease-
specific outcomes against the combined PABC cases [69,
70]. These biologic and therapeutic differences do not
permit pregnancy to sort out as an independent poor-
prognostic factor. Categorizing breast cancer according to
current identifiable biologic subgroups based on ER, PR,
Her 2 status, and tumor grade remains important for
delineation of specific pregnancy effects on cancer out-
comes and will hopefully provide rational clinical guidance
to the co-management of the breast cancer and pregnancy.
A caveat to this approach would be if PABC selects for a
specific breast cancer subtype.
When taken in isolation, those cases pregnant at
diagnosis in the French study and other larger retrospective
reviews faired similarly to reports defining cases as solely
pregnant at diagnosis and it appears the post-partum cases
drove the worsened outcomes for the overall group [66–
68]. Hence, we emphasize the distinction of two PABC
subgroups with PABC diagnosed during pregnancy more
similar to non-PABC when overall outcomes are consid-
ered. The unfortunate delay of diagnosis and poorer
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of concomitant breast cancer with pregnancy [53, 59],
highlights the need for attention to clinical breast exams
and thorough evaluation of breast concerns in pregnancy.
PABC Subset #2: Outcomes when Breast Cancer
is Diagnosed in the High-Risk Period After Pregnancy
Converse to the above data, if one focuses on the reported
cases of women who are diagnosed with breast cancer
subsequently, but within temporal proximity of a completed
pregnancy, increased metastasis and death due to breast
cancer can be consistently identified, including across large
global cohorts [66–68, 71–74]. This worsened prognosis
remains independent when age, tumor stage, tumor biologic
features, and even patient-related confounders of alcohol
use, BMI, education, socioeconomic status, and race [72]
are included. The largest of these series from Norway
reports outcomes from 516 pregnant cases and 531 within
6 months post-partum at time of diagnosis from a cohort of
42,511 cancers. The highest percentages of death from
cancer observed in this study was among cases within
6 months post-partum at 67% versus 44% in pregnant
cases, and 31% in controls [66]. Lactation data was
unavailable for the post-partum group.
The effectofworsenedprognosis inthe post-partumperiod
appearstobetimedependentanddiminishesasincreasedtime
occursbetweenparturitionandbreastcancerdiagnosis.Intwo
large studies,the timeframe ofdiagnosis <2years aftergiving
birth significantly increased hazard ratios for breast cancer
death when compared with parturition ≥5 years prior to
diagnosis or nulliparous women [72, 75]. In one of these
studies, diagnosis within 12 months of parturition had the
worst survival rate at 38%, whereas cases diagnosed 13–
48 months and >48 months post-partum had survival rates of
51% and 60% compared with age-matched nulliparous
women at 65%. Other factors controlled for included age at
first birth, parity, and breastfeeding duration, indicting that a
recent birth alone may be an adverse prognostic factor
among young women diagnosed with breast cancer [75].
Exactly when the effect of a recent birth recedes sufficiently
to no longer impact risk of metastasis and death remains
undefined. A 2008 study of 4,560 British Women with breast
cancer whose last pregnancy was more than 30 years ago
had a 35% reduced risk of dying when compared with
women who had a full-term pregnancy in the 15 years prior
to diagnosis [76], indicating that the number of deaths
complicated by PABC could extend as far as even 15 years
after pregnancy. (Table 2)
Clarity of definition among the subsets of PABC is
important if we are to discern metastatic potential of breast
cancers diagnosed during pregnancy, lactation, or post-
partum. A recent retrospective review of an impressive 668
cases of PABC (pregnant or within 1 year of pregnancy) in
women age 35 or younger concluded that no significant
differences in distant metastasis or overall survival were
found compared with non-PABC. Two reasons for this
disparate conclusion may reflect the author’s choice of
dichotomization between pregnant cases, post-partum
cases, and controls; an issue that may also confound other
studies [66, 71, 77]. Controls in this study were those cases
which did not meet their definition of PABC, however,
these controls would meet the definition defined by the
majority of epidemiologic studies. We have reported that in
women under age 40 at breast cancer diagnosis, 18% will
meet the criteria of being within 2 years and 45% within
6 years of parturition [78]. If the above cited references on
the time frame of post-partum PABC are taken into
consideration, many of the control cases from this recent
report would potentially be better categorized as PABC and
their inclusion may worsen the risk profile of this control
group. A strength of this study is the authors excellent
delineation of their study groups, including that 25/51 cases
of breast cancer diagnosed during pregnancy had treatment
delayed until post-partum. The tumors in these cases were
persistent into the post-partum period and may be therefore
more similar to cancers diagnosed within months of
parturition, which have the worst prognosis of all sub-
groups of PABC [77]. Potentially transferring cases
diagnosed during pregnancy, but untreated until post-
partum to the post-partum grouping may alter the risk
profile of the post-partum cases. However, and most
importantly, these authors definitively report on the success
that can be achieved by rationale and aggressive manage-
ment of these high risk tumors in young mothers [77].
Table 2 Survival statistics for women diagnosed during pregnancy or
post-partum.
% Survival
Study: Non-PABC Pregnant Post-partum
Mathelin et al [68] 97% 72% 63%
Dodds et al [79] 80% NA 6.5–13.6%
Stensheim et al [66] 69% 56% 33%
b
Beadle et al [77] 64.8%
a 62.6% 64.9%
Rodriguez et al [71] 66.6%
a NA 61%
c
Daling et al [72] 75.6–76.7% NA 51.8% (2 years)
Whiteman et al [75] 65% NA 38% (<1 year)
aSome cases may have been within 5 years post-partum, thus some
cases are actually PABC,
bThe authors define lactation period as the
period from date of delivery to 6 months post-partum, therefore these
cases are considered post-partum,
cThis is a mix of reproductive
states: 22% pregnant, 1% diagnosed at delivery, and 76% postpartum.
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in risk of death from breast cancer for mothers dependent
upon time of diagnosis relative to the pregnancy. We
believe this supports the presence of distinct subsets of
PABC based on biologic aggressiveness: those diagnosed
and treated during pregnancy and those diagnosed or
treatment delayed until the post-partum period. Conserva-
tively, control or non-PABC groups may be best defined
using nulliparous cases or cases greater than 10 years post-
partum to mitigate against the uncertainty of when the
effects of PABC become negligible to ensuing breast cancer
prognosis.
Likewise, the data demonstrates that PABC is not a rare
event or niche of breast cancer, but a significant and deadly
subset of the disease that may, in fact, be increasing due to
cultural shifts regarding child-bearing choices. The Cana-
dian 2008 study predicted that an extra 1 in 13 women with
less than 2 years between delivery and diagnosis will die
from their disease compared to women with five or more











Figure 1 Representative human
breast tissue sections across the
pregnancy, lactation, involution
cycle. Human breast tissue
sections collected from age-
matched nulliparous (Nullip)
(a), pregnant (Preg)( b),
lactating (Lac)( c), involuting
(Inv)( d), or fully regressed
(Regr)( e) (>10 years
post-partum) women and stained
by H&E to reveal the complex
and distinct morphology
inherent to each developmental
stage, 200×. Each image depicts
the size of a single lobule
representative of that
developmental stage. Human
tissue was acquired through a
protocol approved by the
Colorado Multi-Institutional
Review Board.
J Mammary Gland Biol Neoplasia (2009) 14:87–98 93these statistics to US birthrates from 2006, when 4.3 million
women experienced live births [80], 25,000 of these
women will be diagnosed with invasive breast cancer and
2,000 may die from their disease within 2 years of giving
birth.
What Drives the Increase in Metastasis of Post-partum
PABC?
If one accepts the data that breast cancer diagnosed during
pregnancy, when stage and biology at diagnosis are taken
into account, does not have a pregnancy-specific poorer
prognosis, and that cases diagnosed within 5 years of
parturition do have a pregnancy-related increased risk, then
it can be proposed that an event associated with pregnancy,
but not pregnancy itself, may facilitate breast cancer
metastasis. We propose that this event is mammary gland
involution [17]. Retrospective evidence that supports this
hypothesis is found in the association of increased
metastatic potential with post-partum breast cancer cases.
Involution is a developmentally-regulated process by which
the fully differentiated milk-producing breast regresses to a
pre-pregnant-like state. Involution occurs at weaning if
lactation occurs or post-partum if lactation does not ensue.
The scale and rapidity of involution is unique to the
mammary gland, involving apoptotic cell death of 50%–
80% of the mammary epithelium, and entails a remodeling
program that returns the gland to a quiescent state [81, 82].
Accumulating evidence indicates that mammary gland
involution utilizes some of the same tissue-remodeling
programs that are activated during wound healing and
inflammation [83, 84]. These similarities include macro-
phage cell influx, elevated levels of the immunomodulators
TGF beta 1 and 3, and matrix metalloproteinase (MMP)-2, -
3, and -9, deposition of fibrillar collagen and the onco-fetal
protein tenascin, and presence of bioactive proteolytic
fragments of the extracellular matrix proteins fibronectin
and laminin. These stromal attributes of wound healing/
inflammation have been causally associated with tumor
progression [17, 23, 85, 86] and may result in dissemina-
tion of tumor cells and metastasis. For example, cells
interact with the extracellular matrix protein fibronectin
through β1 integrins. β1 integrins are required for re-
epithelialization of a wound [87], and β1 integrin loss in
human breast cancers results in tumor suppression [88].
TGF beta also promotes tumor growth indirectly through
activation of the stroma [89], and its upregulation stim-
ulates matrix deposition and proliferation of fibroblasts in
the healing wound [85]. Additionally, increased abundance
of inflammatory cells is a hallmark of human cancers [90,
91] and pre-clinical models of breast cancer demonstrate
that macrophages are required for tumor cell migration,
invasion and metastasis [92]. Angiogenesis and lymphan-
giogenesis, processes that require both MMP activity and
deposition of collagen for formation of new vessels, are
important steps in both wound healing and tumor progres-
sion [93, 94]. Finally, fibronectin is an important compo-
nent of the early wound healing stroma [85] and has been
shown to be a component of the matrices of metastatic
tumors as well [95]. These examples highlight only some of
the similarities that have been observed between wound
healing and tumor progression. Thus, given that a wound
healing microenvironment is tumor promotional, and the
involution microenvironment is similar to that of wound
healing, it can be predicted that involution would promote
cancer. Rodent models of involution confirm increased
metastasis of human breast cancer cells that have been




Figure 2 Immune cells are specifically recruited to actively involut-
ing lobules in normal human mammary tissue. Immune cells as
detected by IHC for common leukocyte antigen CD45 are stained
brown in a breast biopsy from a woman who was actively involuting
at the time of the biopsy, which revealed no malignancy (i.e. normal
tissue). Both lactating (Lac) and involuting (Inv) lobules are present
and highlighted with dashed lines. Scale bar indicates 40μm.
94 J Mammary Gland Biol Neoplasia (2009) 14:87–98over, wound healing and mastitis have been shown to
increase breast cancer risk [97, 98] and other types of
epithelial cancers are known to result from repetitive
wounding and regeneration [85], further implicating the
involution microenvironment in tumor promotion.
Evidence that involution utilizes tissue remodeling
programs reminiscent of wound healing has been obtained
from rodent models, with relevance to women unknown.
As evident in Fig. 1, dramatic morphologic changes occur
in the human mammary gland with reproductive stage.
Elevated proliferation and differentiation during pregnancy
and lactation transform the rudimentary branching structure
of the nulliparous gland into a florid milk-secreting organ
(Fig. 1a–c). During involution, this abundance of prolifer-
ative and differentiated growth then transforms to a marked
desmoplastic regressing environment, as the gland remodels
to a rudimentary structure (Fig. 1d, and data not shown). It
is likely that this involution process will utilize a predict-
able wound healing/inflammatory cascade, such as that
described in rodent models. In human tissue, we have found
that it is common to observe fully lactational lobules
adjacent to involuting lobules. The presence of both
lactating and actively involuting lobules in the same tissue
specimen permits the investigation of microenvironment
changes that are specific to involution, and provides insight
into the potential tumor promoting attributes of this period.
As evident in Fig. 2, immune cells appear to be specifically
recruited to the involuting lobules, as they are much less
abundantintheadjacentlactationallobules.Thisobservation
indicates that the microenvironment surrounding an involut-
ing lobule is distinct from that of a lactational lobule, and
provides compelling evidence that human breast involution
utilizes wound healing programs to remodel after pregnancy.
If a present malignancy is superimposed on such an
inflammatory milieu, then the tumor could be promoted,
resulting in increased metastases compared to a tumor that
has not been exposed to the involution microenvironment.
What Future for PABC: Prevention of the Collision?
In conclusion, while parity may reward women who
give birth when they are younger than thirty-five with
varying degrees of lifetime protection from breast
cancer, it is also true that parous women will experience
a transient increased period of risk for breast cancer
immediately following any childbirth. This transient risk
is further increased by older age at first birth, positive
family history of breast cancer, and in women with
germline mutations in breast cancer susceptibility genes.
Of uncertain significance is the protective effect ob-
served with lactation. When tumors are matched for
known clinical features, women who are diagnosed with
PABC during pregnancy experience outcomes similar to
women diagnosed with non-PABC, indicating that
pregnancy per se is not an independent risk factor for
breast cancer. Conversely, women who are diagnosed
with PABC in the post-partum period have a poorer
prognosis that is independent of known prognostic
factors. We believe a major difference between these
groups is exposure of the tumor cells to the involution
microenvironment, which has attributes of a wound.
Women who are diagnosed during pregnancy and
treated during pregnancy effectively eliminate the lesion
that we propose will be promoted by the involution
microenvironment if left in situ. Mechanisms underlying
the distinct biology of pregnancy-associated tumors that
are promoted by involution are currently being identi-
fied in human and rodent mammary tissues in our labs.
Our ultimate goal is to target the involution period with
intervention strategies that may help eliminate the
increased metastatic potential of PABC.
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